Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study hypothesis:

Growth hormone (GH), through its generation of free 'bioavailable' insulin-like growth factor (IGF)-I, can improve insulin sensitivity in adults with GH deficiency.

Study aims:

The purpose of this study is to determine the mechanism of how low dose GH treatment affects the body's sensitivity to insulin actions and whether this low GH dose can affect the body's handling of steroid hormone levels (cortisol clearance) in adults with GH deficiency.

Study design:

Men and women with confirmed GH deficiency, but not recently been on GH treatment will be invited to participate in this study. The subjects will be assessed at the initial visit to ascertain their suitability before further participating in the study. If suitable, an equal number of men and women will be randomized to receive either low dose GH or placebo injection for 3 months. Before, during and after treatment, the subjects will be assessed at regularly with blood tests, scans and fat biopsies. At the first and final visit, testing will include scans to measure the amount of whole body fat and fat in the stomach area, muscle, and liver; blood tests to measure levels of cortisol, and fat tissue (taken from a biopsy) analysis to measure the density of IGF-I in the muscle; whereas blood tests to examine insulin sensitivity will also be collected. This study will use Genotropin and Genotropin pen devices, and the the data will be analyzed using a computer statistical program where the identity of the subjects will be coded to maintain confidentiality.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Low Dose Growth Hormone Treatment in Subjects With Metabolic Syndrome.

NCT00720616

Metabolic Syndrome

WITHDRAWN NA

Growth Hormone and Glucose Metabolism

NCT00929799

Growth Hormone Deficiency

COMPLETED PHASE4

Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)

NCT01605331

Growth Hormone Deficiency

COMPLETED PHASE4

Metabolic Effects of GH and IGF-I in Growth Hormone Deficient(GHD) and Diabetes and Impaired Glucose Tolerance(IGT)

NCT01020955

Diabetes

COMPLETED PHASE3

Effects of Growth Hormone and IGF-1 on Anabolic Signals and Stem Cell Recruitment in Human Skeletal Muscle

NCT03878992

Growth Hormone Deficiency Growth Hormone Treatment

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will be double-blinded. One hundred subjects will be screened for eligibility initially, and 24 subjects will be enrolled with 12 subjects being randomized to receive the low GH dose (0.1 mg/day) treatment and 12 subjects to receive Placebo treatment for 3 months, allowing a 10% drop-out rate. The subjects will be taught by either by the Endocrine Nurse Specialists to self-administer the GH by subcutaneous injections using a Genotropin pen device.

Visit 1, Initial Screening Assessment (as out-patient)

* Physical examination, weight, height, and waist circumference measurements
* Fasting blood glucose levels

Visit 2, Baseline Assessment (as in-patient)

* Physical examination, weight, height, and waist circumference measurements
* Fasting blood tests for glucose, insulin, C-peptide, free IGF-I, total IGF-I, IGF-2, IGFBPs -1 and -3, non-esterified fatty acid and lipid profiles
* MRS, abdominal CT and DEXA scans
* One-step 3-hour hyperinsulinaemic euglycaemic clamp
* Cortisol production rates and urine cortisol collections
* Fat biopsies will be taken at the end of the assessment of cortisol production rates

Visit 3, Interim Assessment (Month 1) (as out-patient)

* Documentation of any adverse effects
* Fasting blood tests for glucose, insulin, C-peptide, free IGF-I, total IGF-I, IGF-2, IGFBPs -1 and -3

Visit 4, Final Assessment (Month 3) (as in-patient)

* Physical examination, weight, height, and waist circumference measurements
* Fasting blood tests for glucose, insulin, C-peptide, free IGF-I, total IGF-I, IGF-2, IGFBPs -1 and -3, non-esterified fatty acid and lipid profiles
* MRS, abdominal CT and DEXA scans
* One-step 3-hour hyperinsulinaemic euglycaemic clamp
* Cortisol production rates and urine cortisol collections
* Fat biopsies will be taken at the end of the assessment of cortisol production rates

Any extra blood remaining from the samples of blood drawn may be banked indefinitely with confidential identifiers, and may be given to researchers in the future to examine for other potential causes of diabetes and heart diseases in adults. These blood samples, however, will not be used for genetic studies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Growth Hormone Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Growth hormone

Group Type ACTIVE_COMPARATOR

Growth hormone (Genotropin)

Intervention Type DRUG

Growth hormone 0.1 mg self-injected once a day subcutaneously at bedtime.

B

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo self-injected once a day subcutaneously at bedtime.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Growth hormone (Genotropin)

Growth hormone 0.1 mg self-injected once a day subcutaneously at bedtime.

Intervention Type DRUG

Placebo

Placebo self-injected once a day subcutaneously at bedtime.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Genotropin Placebo.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age range 18 to 75 years
* BMI should not exceed 40 kg/m2
* Confirmed GH deficient with at least one provocative test, e.g. insulin tolerance test and/ or GHRH/arginine
* Not received any GH therapy within last 6 months
* On a stable standardized hydrocortisone replacement dose regimen (twice a day at 8 AM and 4 PM),
* If any other pituitary hormone deficiencies are present, patient must be on optimal pituitary hormone replacement therapy, e.g. Thyroxine, testosterone and oestrogen replacement
* Normal renal and hepatic function
* Prepared to self-inject

Exclusion Criteria

* Untreated or subclinically hypo/hyperthyroid
* Untreated or subclinically treated hypocortisolism
* Type 1 or 2 diabetes mellitus
* Subjects with evidence of nephropathy from any cause
* Subjects with evidence of retinopathy from any cause
* Any other medical illnesses that may affect the interpretation of the results
* Pregnant
* Emotional/social instability likely to prejudice study completion
* Previous history of known malignancy
* Recurrent or severe unexplained hypoglycaemia
* Known or suspected drug/alcohol abuse

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No